Dyne Therapeutics, Inc.
DYNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company carries a $2.92B market cap, placing it firmly in the mid-cap category. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Market Cap
$2.92B
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-4.68
EPS (TTM)
$-3.26
EPS (Fwd)
$-3.34
ROE
-81.6%
ROA
-39.0%
Cash
$898.5M
Total Debt
$233.3M
Free CF
-$317.1M
52W Change
-8.8%
Annual Financials
Cash vs Debt
Where DYN stands vs its 150-day and 200-day moving averages
As of the October 8, 2026 close, DYN finished 21.21% below its 150-day moving average ($20.27) and 18.35% below its 200-day moving average ($19.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DYN overbought or oversold?
At the October 8, 2026 close, DYN's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $898.5M in cash comfortably exceeding the $233.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$317.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -81.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, DYN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Dyne Therapeutics, Inc. and its sector.